Carvedilol Reduces Elevated B-type Natriuretic Peptide in Dialyzed Patients Without Heart Failure: Cardioprotective Effect of the Beta-blocker.
From: Department of Internal Medicine, Komono Kosei Hospital, Komono, Japan.
Journal of cardiovascular pharmacology
- Publish Date: Apr 2007
- ISSN: 0160-2446
- Volume: 49
- Issue: 4
- Pages: 191-6
- Medium: Print
- Language: English
- Citation (JAMA): Kojima Masayoshi, Sato Koichi, Kimura Genjiro, et al. Carvedilol Reduces Elevated B-type Natriuretic Peptide in Dialyzed Patients Without Heart Failure: Cardioprotective Effect of the Beta-blocker.. J. Cardiovasc. Pharmacol. Apr 2007;49:191-6
Abstract
Elevated plasma B-type natriuretic peptide (BNP) predicts future cardiovascular events in dialyzed patients without heart failure. We investigated whether carvedilol reduces the elevated BNP in these patients. Asymptomatic patients on chronic hemodialysis with elevated BNP but without clinical signs of heart failure were randomly assigned to receive either carvedilol (n = 10) or nothing (control group, n = 10). BNP and malondialdehyde-low density lipoprotein (MDA-LDL) were measured, and ultrasound cardiography was performed at baseline and at 3 months. Carvedilol reduced the concentrations of BNP (551 +/- 90 to 237 +/- 174 ng/L, P < 0.01) and MDA-LDL (174 +/- 63 to 85 +/- 23 U/L, P < 0.01) and increased the velocity ratio of E to A waves of the transmitral flow (E/A: 0.59 +/- 0.04 to 0.71 +/- 0.05, P < 0.05), while no such alterations were observed in the control group. The reduction in BNP concentration was correlated with that in MAD-LDL and the increase in the E/A. There was a significant correlation between the increase in the E/A and the reduction in MDA-LDL concentration. Thus, carvedilol reduces the elevated BNP by improving left ventricular diastolic function in dialyzed patients without heart failure, which may be attributable to the antioxidant property of the beta-blocker. Administering carvedilol may improve the prognosis in this population.
Mesh Headings (Keywords): Adrenergic beta-Antagonists, Adult, Aged, Biological Markers, Blood Flow Velocity, Blood Pressure, C-Reactive Protein, Carbazoles, Female, Heart Failure, Heart Rate, Humans, Interleukin-6, Lipoproteins, LDL, Male, Malondialdehyde, Middle Aged, Natriuretic Peptide, Brain, Propanolamines, Renal Dialysis, Research Design, Stroke Volume, Treatment Outcome, Ventricular Function, Left
Check for Full Text / PubMed Unique Identifier (PMID): 17438403
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.